Brief: Pixium Vision Receives FDA Approval For Prima System Clinical Trial At Stanford University
29/03/2022 06:38
March 29 (Reuters) - Pixium Vision SA ALPIX.PA :
* PIXIUM VISION ANNOUNCES FDA APPROVAL OF CLINICAL TRIAL
EXPANSION
OF PRIMA SYSTEM US FEASIBILITY STUDY TO STANFORD MEDICINE
* FDA APPROVES NEW ADDITIONAL STUDY LOCATION AT STANFORD
MEDICINE
* DATA READOUT IS EXPECTED IN 2023
* US FEASIBILITY STUDY WILL RECRUIT 5 PATIENTS
* PIVOTAL STUDY OF PRIMA SYSTEM IS UNDERWAY IN SEVERAL
EUROPEAN
COUNTRIES
Source text for Eikon: urn:newsml:reuters.com:*:nGNE6SfLNS
Further company coverage: ALPIX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;))
Recent news on Pixium Vision SA
See all newsBrief: Pixium Vision SA Says Paris Commercial Court Postponed Decision On Takeover Offer Filed On Nov 20, 2023
Brief: Pixium Vision: opening of judicial liquidation proceedings has been postponed to later date
Brief: Pixium Vision Announces Decision About Adoption Of Sale Plan, Opening Of Judicial Liquidation Proceedings Planned For Jan 16, 2024
Brief: Pixium Vision SA Announces Conversion Of Safeguard Proceedings Into Receivership
Brief: Pixium Vision Announces Tender Process For Purpose Of Finding Buyers To Acquire Company's Business Will Be Published Tomorrow